摘要
心律失常的发生机制复杂,且临床上应用于治疗心律失常的药物治疗效果不佳。近年来很多研究发现L型钙通道的异常与心律失常密切相关。CaV1.2为心肌中L型钙离子通道的主要亚型,近期研究发现CaV1.2蛋白及mRNA表达异常与心律失常的发生发展密切相关,并且CaV1.2相关的治疗心律失常的药物在心律失常中治疗效果显著,因此CaV1.2有望作为治疗心律失常的新靶点。现重点介绍通过干预CaV1.2治疗心房颤动、长QT间期综合征以及Brugada综合征等心律失常的最新研究进展。
The pathogenesis of arrhythmia is complex and the therapeutic effect of drug for arrhythmia is not well. In recent years, many studies have found that abnormal L-type calcium channels are closely related to the occurrence and development of a variety of arrhythmias. CaV1.2 is the main subtype of L-type calcium channel in myocardium. Recent studies have found that abnormal expression of CaV1.2 is closely related to the occurrence and development of a variety of arrhythmias, and drugs related to CaV1.2 for arrhythmia have significant therapeutic effects. Therefore, CaV1.2 is expected to be a new target for arrhythmia’s treatment. This article focuses on the latest research progress in interventing CaV1.2 for atrial fibrillation, long QT interval syndrome and Brugada syndrome.
作者
娄奇
李为民
LOU Qi;LI Weimin(Graduate School of Harbin Medical University, Harbin 150001, Heilongjiang, China;Department of Cardiology,The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China)
出处
《心血管病学进展》
CAS
2019年第6期919-923,共5页
Advances in Cardiovascular Diseases
基金
哈尔滨高层次人才基金(2013SYYRCYJ06)
